Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
评估基于炎症的改良格拉斯哥预后评分（mGPS）作为接受一线化疗的转移性结直肠癌患者的预后和预测生物标志物：随机 III 期 XELAVIRI 试验（AIO KRK0110）的事后分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103374
Boukovala, M; Modest, D P; Ricard, I; Fischer von Weikersthal, L; Decker, T; Vehling-Kaiser, U; Uhlig, J; Schenk, M; Freiberg-Richter, J; Peuser, B; Denzlinger, C; Peveling Genannt Reddemann, C; Graeven, U; Schuch, G; Schwaner, I; Heinrich, K; Neumann, J; Jung, A; Held, S; Stintzing, S; Heinemann, V; Michl, M
